Basimglurant is under clinical development by Noema Pharma and currently in Phase III for Trigeminal Neuralgia (Tic Douloureux). According to GlobalData, Phase III drugs for Trigeminal Neuralgia (Tic Douloureux) have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Basimglurant’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Basimglurant overview

Basimglurant (RG7090, RO4917523, R7090) is under development for the treatment of stuttering, seizures associated with tuberous sclerosis complex (TSC) and for the management of pain associated with trigeminal neuralgia (TN).  Basimglurant is a mGluR5 (metabotropic glutamate receptor 5) antagonist.

It was also under development for the treatment of treatment-resistant depression, anxiety, major depressive disorder and fragile X syndrome. The drug candidate is administered orally.

Noema Pharma overview

Noema Pharma (Noema) is a biotechnology company that discovers and develops treatment for orphan diseases of brain and central nervous system. The company is developing NOE-101, a mGluR5 inhibitor for treatment of tuberous sclerosis complex (TSC) and severe pain in trigeminal neuralgia (TN). It is also investigating NOE-105, a PDE10A inhibitor that modulates dopamines D2 receptors to treat tourette syndrome. The company was funded by Sofinnova Partners, Glide healthcare, Invus, Roche, BioMed Partners and Polaris Partners. Noema is headquartered in Basel, Basel-Stadt, Switzerland.

For a complete picture of Basimglurant’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.